Liu Changxing, Talmor Guy, Low Garren Mi, Wang Tiffany V, Mann Daljit S, Sinha Uttam K, Kokot Niels C
USC Tina and Rick Caruso Department of Otolaryngology - Head and Neck Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Clin Med Insights Ear Nose Throat. 2018 Aug 19;11:1179550618792248. doi: 10.1177/1179550618792248. eCollection 2018.
Human papillomavirus (HPV)-positive and HPV-negative oropharyngeal squamous cell carcinomas (OPSCCs) are 2 distinct cancers, with HPV-positivity conferring a better prognosis. Smoking status is a complicating factor for both patient populations. There have been scattered literature that have reported on incomplete information regarding the profiles of their patient population. Details including age and sex distributions, TNM staging, histology grading, recurrence time and types, death rates, and the direct causes of deaths have been reported incompletely in the literature. Here, based on the experience at our university medical centers, we explored all the details of the important clinical profiles of HPV-negative OPSCC, HPV-positive OPSCC in smokers and nonsmokers.
In this article, we compare detailed clinical profiles of HPV-negative OPSCC and HPV-positive OPSCC in both smokers and nonsmokers. The clinical profiles we elucidated here include patients' age and sex distribution, general health conditions, histology grading, TNM staging, perineural invasion (PNI), and lymphovascular invasion (LVI), extracapsular extension (ECE), recurrence rate and types, death rate, and direct causes. Specifically, we divided HPV-positive OPSCC into smokers and nonsmokers and compared the different clinical profiles between these groups to give a better idea of the complicating role of smoking in the development of HPV-positive OPSCC.
All patients with OPSCC at a tertiary care publicly funded county hospital and a tertiary care university hospital from June 2009-July 2015 were retrospectively reviewed. The attending physicians were the same at both hospitals. The primary outcome measure was posttreatment 2-year follow-up status (locoregional recurrence, distant recurrence, death rate). Other measures included HPV status based on p16 staining, smoking history, age, sex, comorbidities, tumor size, nodal and distant metastasis information, LVI, PNI, ECE, and tumor histology grade.
A total of 202 patients with OPSCC were identified. They were categorized into 3 groups: HPV-negative OPSCC group (HPV-), HPV-positive smoker group (HPV+SMK+), and HPV-positive nonsmoker group (HPV+SMK-). Patients of HPV- group are older (61.1 ± 11.6 years) than the other groups on average. The HPV- group has the highest percentage of women (22.7%). The HPV- patients with OPSCC have more comorbidities than the HPV+SMK+ group and the HPV+SMK- group, although there is no statistical difference. Grade 2 tumor is the most common histology grade for HPV- patients with OPSCC, whereas grade 3 is the most common grade for HPV+SMK+ and HPV+SMK- groups. Both PNI and LVI are positive at around 40% for all groups without any significant difference, but ECE is very common for HPV- OPSCC, at 86.7%, which is significantly higher than that of the HPV+SMK+ and HPV+SMK- groups. There was no difference of bilateral neck metastases noticed among different groups. For T staging and N staging, although HPV+SMK- and HPV+SMK+ patients have relatively lower T stages and higher N stages, there is no significant difference. HPV+SMK- group has highest TNM stages. All death rates and recurrence rates increase with time, but the death rate of HPV- group is about 4 times higher than that of the HPV+SMK+ group and 6 times higher than that of the HPV+SMK+ group. The major recurrence type of HPV- OPSCC and HPV+SMK+ is locoregional, and the major recurrence type of HPV+SMK+ is distant metastasis.
Our data confirmed that HPV+ OPSCC normally presents with more advanced stage, however, it has better prognosis. In comparison, HPV- OPSCC presents at an earlier stage, but the prognosis is worse. Based on their clinical profiles, we noted that HPV-positive OPSCC cells are more "mobile"; they metastasize sooner and further. However, HPV-negative OPSCC cells are more locally infiltrative, leading to more locoregional recurrence. The HPV-positive patients usually are younger and healthier at diagnosis. Although HPV-positive OPSCC tend to be histologically higher grades, there was no statistical difference noticed. Metastatic and recurrent patterns are very different between HPV-positive and HPV-negative patients, but the death rate of HPV-negative patients is way higher, and it is mainly due to locoregional recurrences, which is the major recurrence type for HPV-negative patients. Of our note, smoking is a complicating factor for HPV-positive OPSCC, and it makes the death rate, recurrence rate, histology grade, and TNM staging shift toward HPV-negative OPSCC. How smoking makes HPV-positive OPSCC behave more like OPSCC-negative OPSCC deserves more translational research for further elucidation.
人乳头瘤病毒(HPV)阳性和HPV阴性的口咽鳞状细胞癌(OPSCC)是两种不同的癌症,HPV阳性患者预后较好。吸烟状况是这两类患者群体的一个复杂因素。已有一些文献报道了关于其患者群体特征的不完整信息。包括年龄和性别分布、TNM分期、组织学分级、复发时间和类型、死亡率以及死亡直接原因等细节在文献中报道得并不完整。在此,基于我们大学医学中心的经验,我们探究了HPV阴性OPSCC、吸烟者和非吸烟者中HPV阳性OPSCC重要临床特征的所有细节。
在本文中,我们比较了吸烟者和非吸烟者中HPV阴性OPSCC与HPV阳性OPSCC的详细临床特征。我们在此阐述的临床特征包括患者的年龄和性别分布、总体健康状况、组织学分级、TNM分期、神经周围浸润(PNI)和淋巴管浸润(LVI)、包膜外扩展(ECE)、复发率和类型、死亡率以及直接原因。具体而言,我们将HPV阳性OPSCC分为吸烟者和非吸烟者,并比较这些组之间不同的临床特征,以便更好地了解吸烟在HPV阳性OPSCC发生发展中的复杂作用。
回顾性分析了2009年6月至2015年7月在一家三级护理公立县级医院和一家三级护理大学医院就诊的所有OPSCC患者。两家医院的主治医生相同。主要观察指标是治疗后2年的随访状态(局部区域复发、远处复发、死亡率)。其他指标包括基于p16染色的HPV状态、吸烟史、年龄、性别、合并症、肿瘤大小、淋巴结和远处转移信息、LVI、PNI、ECE以及肿瘤组织学分级。
共确定了202例OPSCC患者。他们被分为3组:HPV阴性OPSCC组(HPV-)、HPV阳性吸烟者组(HPV+SMK+)和HPV阳性非吸烟者组(HPV+SMK-)。HPV-组患者的平均年龄(61.1±11.6岁)高于其他组。HPV-组女性比例最高(22.7%)。HPV阴性OPSCC患者的合并症比HPV+SMK+组和HPV+SMK-组更多,尽管无统计学差异。2级肿瘤是HPV阴性OPSCC患者最常见的组织学分级,而3级是HPV+SMK+组和HPV+SMK-组最常见的分级。所有组的PNI和LVI阳性率均约为40%,无显著差异,但ECE在HPV阴性OPSCC中非常常见,为86.7%,显著高于HPV+SMK+组和HPV+SMK-组。不同组之间双侧颈部转移无差异。对于T分期和N分期,尽管HPV+SMK-和HPV+SMK+患者的T分期相对较低,N分期较高,但无显著差异。HPV+SMK-组的TNM分期最高。所有死亡率和复发率均随时间增加,但HPV-组的死亡率约为HPV+SMK+组的4倍,为HPV+SMK-组的6倍。HPV阴性OPSCC和HPV+SMK+的主要复发类型是局部区域复发,HPV+SMK-的主要复发类型是远处转移。
我们的数据证实,HPV阳性OPSCC通常表现为更晚期,但预后较好。相比之下,HPV阴性OPSCC表现为早期,但预后较差。基于其临床特征,我们注意到HPV阳性OPSCC细胞更“易转移”;它们转移更早且更远。然而,HPV阴性OPSCC细胞更具局部浸润性,导致更多局部区域复发。HPV阳性患者在诊断时通常更年轻且健康状况更好。尽管HPV阳性OPSCC在组织学上往往分级更高,但无统计学差异。HPV阳性和阴性患者的转移和复发模式非常不同,但HPV阴性患者的死亡率更高,主要是由于局部区域复发,这是HPV阴性患者的主要复发类型。值得注意的是,吸烟是HPV阳性OPSCC的一个复杂因素,它使死亡率、复发率、组织学分级和TNM分期向HPV阴性OPSCC转变。吸烟如何使HPV阳性OPSCC表现得更像HPV阴性OPSCC值得更多转化研究以进一步阐明。